Method Of Altering The Differentiation State Of The Cell Patents (Class 435/377)
  • Patent number: 10426799
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: December 21, 2013
    Date of Patent: October 1, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 10421961
    Abstract: Some embodiments of the invention comprise methods, systems, and compositions to selectively induce, whether in vitro or in vivo, the neuronal differentiation of multipotent stromal cells through the application of microRNAs, including but not limited to miRNA-124, miRNA-137 and/or miRNA-9* expression products of those miRNAs, and molecules and compositions containing functional elements of those miRNAs. Some embodiments of the invention also comprise the therapeutic administration and use of such induced cells to treat mammalian injuries and diseases, including but not limited to, nervous system injuries or diseases that may otherwise result in decreased cell or system function.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: September 24, 2019
    Assignee: EXOSTEM BIOTEC LTD
    Inventors: Chaya Brodie, Shimon Slavin
  • Patent number: 10420803
    Abstract: Cell populations of intestinal midgut endoderm cells and methods of generating the cells expressing markers characteristic of intestinal endoderm lineage are disclosed. Methods of treating conditions such as diabetes are also disclosed.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: September 24, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Sebastian Rieck, Alireza Rezania
  • Patent number: 10421942
    Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: September 24, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
  • Patent number: 10392602
    Abstract: Provided is a method of producing a lacrimal gland epithelial cell from a pluripotent stem cell, a lacrimal gland epithelial cell produced by the method, and a reagent kit for inducing differentiation from a pluripotent stem cell into a lacrimal gland epithelial cell. A method of producing a lacrimal gland epithelial cell includes the following step A: Step A: a step including increasing expression of Pax6 gene in a pluripotent stem cell or transfecting PAX6 protein thereinto, and increasing expression of Foxc1 gene or Foxp1 gene in the pluripotent stem cell or transfecting FOXC1 protein or FOXP1 protein thereinto.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: August 27, 2019
    Assignee: KEIO UNIVERSITY
    Inventors: Masatoshi Hirayama, Minoru Ko
  • Patent number: 10294449
    Abstract: A substrate for culturing cells that includes at least one fiber scaffold adapted to be contained within a disposable or non-disposable bioreactor, wherein the fiber scaffold further includes polymer fibers that have been created by electrospinning, and wherein the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: May 21, 2019
    Assignee: NANOFIBER SOLUTIONS, LLC
    Inventor: Jed K. Johnson
  • Patent number: 10260041
    Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: April 16, 2019
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Stuart Chambers, Lorenz Studer
  • Patent number: 10226487
    Abstract: The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: March 12, 2019
    Assignee: IsletOne AB
    Inventors: Karl-Henrik Grinnemo, Oscar Simonson, Matthias Corbascio, Christer Sylvén, Eva Wärdell
  • Patent number: 10202579
    Abstract: The present invention relates to the directed differentiation of mammalian pluripotent stem cells, especially human pluripotent stem (hPS) cells, into endodermal cells. In particular, the present invention relates to the treatment of mammalian pluripotent stem cells, especially hPS cells, with a DNA demethylating agent while undergoing differentiation into endodermal. The inventors have, as disclosed herein, found that exposing differentiating mammalian pluripotent stem cells, especially hPS cells, to a DNA demethylating agent leads to an improved morphology and improved yield of endodermal cells. The treatment with a DNA de-methylating agent also leads to a significant down-regulation of expression of the stem cell marker Oct4 and to an improved expression of endoderm specific markers, notably sox17, cxcr4 and hhex.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: February 12, 2019
    Assignee: Takara Bio Europe AB
    Inventors: Barbara Küppers-Munther, Josefina Edsbagge
  • Patent number: 10202580
    Abstract: The present invention provides a method for producing adult oligodendrocyte progenitor cells from proliferative oligodendrocyte progenitor cells, and a pharmaceutical composition having for an active ingredient thereof adult OPC produced according to that method. The method for producing adult OPC of the present invention is characterized by inducing proliferating OPC to differentiate into adult OPC by culturing in the presence of a ligand of a thyroid hormone receptor or retinoic acid receptor in a low oxygen environment. The present invention further provides adult OPC produced according to the production method of the present invention, and a pharmaceutical composition having these adult OPC as an active ingredient thereof.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: February 12, 2019
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Makoto Suematsu, Yasuhito Tokumoto, Shinpei Tamaki
  • Patent number: 10190096
    Abstract: Disclosed herein are methods for generating SC-? cells, and isolated populations of SC-? cells for use in various applications, such as cell therapy.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 29, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Douglas A. Melton, Jeffrey R. Millman
  • Patent number: 10160950
    Abstract: Methods for expanding proliferating populations of neuronal subtype-specific progenitors and creating substantially pure populations of motor neurons are provided herein. In particular, the present invention provides methods for maintaining the unique gene profile and differentiation potential of neuronal subtype-specific progenitors, such as motor neuron progenitors and hindbrain serotonergic neural progenitors.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: December 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Zhongwei Du
  • Patent number: 10100284
    Abstract: A synthetic peptide having a stem cell differentiation-inducing activity to induce differentiation of pluripotent stem cells into endodermal cells, a stem cell differentiation inducer having this peptide as an active ingredient, and a method for inducing differentiation of pluripotent stem cells using these. The synthetic peptide provided by the present invention contains a stem cell differentiation-inducing peptide sequence, and this stem cell differentiation-inducing peptide sequence is selected from (1) an amino acid sequence constituting a signal peptide in any of amyloid precursor proteins (APP), amyloid precursor-like protein (APLP) 1 and APLP2, which are known as proteins belonging to the APP family, (2) a partial amino acid sequence constituting the signal peptide, or (3) a modified amino acid sequence formed by substitution, deletion and/or addition of 1, 2 or 3 amino acid residues in these amino acid sequences.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: October 16, 2018
    Assignee: TOAGOSEI CO. LTD.
    Inventors: Kenichi Tanaka, Tetsuhiko Yoshida, Nahoko Baileykobayashi
  • Patent number: 10081792
    Abstract: The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: September 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Nicholas E. Propson, Michael P. Schwartz, Zhonggang Hou, Gene I. Uenishi, Igor I. Slukvin, William L. Murphy, Jue Zhang
  • Patent number: 10077428
    Abstract: The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: September 18, 2018
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Gordon Keller, Lei Yang, Steven Kattman
  • Patent number: 10077429
    Abstract: The present invention provides a method of improving iPS cell establishment efficiency, comprising contacting a protein involved in primitive streak (PrS) formation, preferably Foxh1, or a nucleic acid that encodes the same with a somatic cell in a nuclear reprogramming step. Also provided is a method of producing an iPS cell, comprising contacting the protein involved in PrS formation or a nucleic acid that encodes the same, and nuclear reprogramming substance(s) with a somatic cell.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: September 18, 2018
    Assignee: Kyoto University
    Inventors: Kazutoshi Takahashi, Koji Tanabe, Shinya Yamanaka
  • Patent number: 10072249
    Abstract: The purpose of the present invention is to provide a process or method that can be utilized when deriving a three-dimensional structure of a kidney from pluripotent stem cells such as ES cells or iPS cells. The differentiation inducing method is characterized by culturing pluripotent cells with the following three steps, in order: (a) a step of culturing an embryoid body induced from the pluripotent stem cells in medium containing Bmp4 and a high-concentration (concentration A) Wnt agonist; (b) a step of culturing the embryoid body in medium which contains activin, Bmp4, retinoic acid and a middle-concentration (concentration B) Wnt agonist; and (c) a step of culturing the embryoid body in medium containing Fgf9 and a low-concentration (concentration C) Wnt agonist (herein, the Wnt agonist concentrations is concentration A>concentration B>concentration C).
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: September 11, 2018
    Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Ryuichi Nishinakamura, Atsuhiro Taguchi
  • Patent number: 10072243
    Abstract: This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: September 11, 2018
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Young Gie Chung, Robert P. Lanza, Irina V. Klimanskaya
  • Patent number: 10011819
    Abstract: Provided are a culture medium for preparing neural stem cell and use thereof, the culture medium for preparing neural stem cell comprising: a basic culture medium suitable for the growth of stem cell, and a cell signal pathway inhibitor selected from at least one of GSK inhibitor, MEK inhibitor, TGF-? inhibitor, ROCK inhibitor and BMP inhibitor.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: July 3, 2018
    Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Guangjin Pan, Duanqing Pei, Lihui Wang, Linli Wang, Yanting Xue
  • Patent number: 9994825
    Abstract: Described are methods for differentiating mammalian pluripotent stem cells towards a population of cells that can self-organize into vascular networks in vitro when harvested cells of the present invention are embedded into a hydrophilic matrix such as a hydrogel.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 12, 2018
    Assignee: The Johns Hopkins University
    Inventors: Sharon Gerecht, Sravanti Kusuma
  • Patent number: 9909161
    Abstract: A method and system for evaluating the competence for transplantation of a graft sample containing cells capable of multinucleation are provided. In one form, the method includes determining multinucleating ability as an indicator representing the capacity for multinucleation of the cells capable of multinucleation.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: March 6, 2018
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventor: Kenta Sakamoto
  • Patent number: 9822342
    Abstract: The present invention provides a method for efficiently producing cardiomyocytes from pluripotent stem cells, which method comprises the steps of dissociating embryoid bodies obtained during the production process, and allowing reaggregation of the resulting cells to allow formation of embryoid bodies.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 21, 2017
    Assignee: KYOTO UNIVERSITY
    Inventors: Shinya Yamanaka, Yoshinori Yoshida, Kenji Miki
  • Patent number: 9771558
    Abstract: The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37° C. during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: September 26, 2017
    Assignee: DANDRIT DIOTECH A/S
    Inventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen
  • Patent number: 9765292
    Abstract: A bioreactor for preferably three-dimensional cell culturing comprises a scaffold chamber, a first tube, a second tube and a first valve with a scaffold adapter, a tube adapter and a medium adapter. The first valve has a housing with a longitudinal female portion ending in an opening and a longitudinal actuator being arranged through the opening of the female portion of the housing such that the actuator is arranged partially inside the housing and partially outside the housing, wherein the actuator of the first valve is axially moveable relative to the housing of the first valve between a first position in which the first valve is in the operation position and a second position in which the first valve is in the medium change position. By providing the actuators in the first valve which is applied by axial movements, operation of the bioreactor can be comparably simple and safe.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: September 19, 2017
    Assignees: University Hospital of Basel, Cellec Biotek AG
    Inventors: Elia Piccinini, David Wendt, Adam Papadimitropoulos, Laura Spinelli, Stefania Adele Riboldi, Francesco Giovanni Greco, Peter Iwatschenko
  • Patent number: 9765297
    Abstract: The present invention relates to culture systems comprising differentiated stem cells, that may be used for identifying agents useful in treating degenerative nervous system disorders and are suitable for high-throughput screening applications. It is based, at least in part, on the discovery that co-cultures of (i) astrocytes expressing a mutated SODI gene and (ii) stem-cell derived motor neurons manifested cell death via a Bax-dependent mechanism, and modeled motor neuron death in amyotrophic lateral sclerosis.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: September 19, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Serge Przedborski, Hynek Wichterle, Makiko Nagai, Thomas M. Jessell
  • Patent number: 9752125
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater than 50% of the cells in the population co-express PDX1 and NKX6.1.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: September 5, 2017
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 9744195
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: August 29, 2017
    Assignee: LifeScan, Inc.
    Inventor: Jean Xu
  • Patent number: 9738906
    Abstract: An object of the present invention is to provide a method of promoting polyploidization of megakaryocytes and thereby producing highly polyploidized megakaryocytes, a method of efficiently producing platelets from polyploidized megakaryocytes, and the like. The present invention provides a method of producing polyploidized megakaryocytes comprising a step of forcing expression of an apoptosis suppressor gene in megakaryocytes before polyploidization and culturing the resulting cells.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: August 22, 2017
    Assignee: The University of Tokyo
    Inventors: Koji Eto, Hiromitsu Nakauchi, Naoya Takayama, Sou Nakamura
  • Patent number: 9700531
    Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: July 11, 2017
    Assignee: Catholic University Industry Academic Cooperation Foundation
    Inventors: Mi-La Cho, Seon-Yeong Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jun-Geol Ryu
  • Patent number: 9657272
    Abstract: The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: May 23, 2017
    Assignee: Georgetown University
    Inventors: Richard Schlegel, Xuefeng Liu
  • Patent number: 9605243
    Abstract: Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: March 28, 2017
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel Edward Baetge
  • Patent number: 9593310
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: March 14, 2017
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 9546354
    Abstract: Immune cells (Z cells) activated by zinc finger-like protein that regulates apoptosis (Zfra) and uses thereof in cancer treatment.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: January 17, 2017
    Assignee: National Cheng Kung University
    Inventors: Nan-Shan Chang, Chen-Yu Lu, Wan-Pei Su, Yu-An Chen, Wang Wan Jen
  • Patent number: 9540613
    Abstract: A method of culturing human pluripotent stem cells to produce pancreatic lineage, the method comprising the steps of (a) culturing the stem cells in the presence of a chemically defined medium comprising an effective amount of FGF, Activin A, and BMP; (b) culturing the cells from step (a) in the presence of a chemically defined medium comprising an effective amount of insulin, transferrin, and selenium (ITS), and FGF; (c) culturing the cells from step (b) in the presence of a chemically defined medium comprising an effective amount of insulin, transferrin, and selenium (ITS), and Noggin-Nicotinamide-Retinoic acid; and (d) culturing the cells from step (c) in the presence of a serum free chemically defined medium (ITSFINE and Noggin) comprising an effective amount of ITS, FGF7, islet neogenesis associated peptide (INGAP), nicotinamide, and Exendin-4, wherein pancreatic lineage cells are produced, wherein the pancreatic lineage cells are insulin+ cells.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: January 10, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jon Scott Odorico, Xiaofang Xu, Melisa Wittkowske
  • Patent number: 9534205
    Abstract: The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: January 3, 2017
    Assignee: The Scripps Research Institute
    Inventors: Yan Shi, Caroline Desponts, Sheng Ding, Hongyan Zhou, Tongxiang Lin, Wenlin Li, Saiyong Zhu
  • Patent number: 9504716
    Abstract: Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: November 29, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: Marc H. Hedrick, John K. Fraser, Susan Lynn Riley, Ronda Elizabeth Schreiber
  • Patent number: 9506037
    Abstract: A bicellular vascular population derived from human pluripotent stem cells (hPSCs) undergoes morphogenesis and assembly in a synthetic hydrogel. It is shown that hPSCs can be induced to co-differentiate into early vascular cells (EVCs) in a clinically-relevant strategy dependent upon Notch activation. These EVCs mature into ECs and pericytes, and self-organize to form vascular networks in an engineered matrix. Upon in vivo implantation, multicellular human vascular networks are functionally perfused. Thus, a derived bicellular population is exploited for its intrinsic self-assembly capability to create functional microvasculature in a deliverable matrix.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 29, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Sharon Gerecht, Sravanti Kusuma
  • Patent number: 9499794
    Abstract: The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: November 22, 2016
    Assignee: BioLamina AB
    Inventors: Karl Tryggvason, Karl Kristian Tryggvason, Anna Domogatskaya
  • Patent number: 9499797
    Abstract: A method of producing an induced pluripotent stem cell includes introducing into a somatic cell one or more non-viral expression vectors. The vectors include one or more of an Oct family gene, a Klf family gene, a Sox family gene, a Myc family gene, a Lin family gene, and Nanog gene. The somatic cell is then cultured in a medium that supports pluripotent stem cells. At least a portion of the one or more introduced non-viral expression vectors is not substantially integrated in the chromosome.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: November 22, 2016
    Assignee: KYOTO UNIVERSITY
    Inventors: Shinya Yamanaka, Keisuke Okita
  • Patent number: 9480727
    Abstract: This invention provides an artificially synthesized peptide having an activity to inhibit the expression of type 2 TNF receptor (TNF-R2), and a TNF-R2 expression-inhibiting composition including the peptide as an active ingredient. Also provided is a method for inhibiting the expression of TNF-R2 in cells capable of expressing TNF-R2, by using the peptide. The expression of TNF-R2 in the cells is inhibited, by supplying the cells capable of expressing TNF-R2 with a synthetic peptide essentially including of an amino acid sequence constituting a signal peptide in an amyloid precursor protein (APP) or an amino acid sequence formed by substituting, deleting and/or adding one or several amino acid residues in/from/to the amino acid sequence of the signal peptide.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: November 1, 2016
    Assignee: TOAGOSEI CO. LTD.
    Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida
  • Patent number: 9457053
    Abstract: Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 4, 2016
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee
  • Patent number: 9458428
    Abstract: The invention relates to the field of cell culture, specifically, the derivation of retinal pigmented epithelial cells from pluripotent cells. The invention comprises the use of various cell culture medium supplements, medium formulations, and methods of using such medium supplements and formulations, in order to effect the rapid differentiation of pluripotent cells into retinal pigmented epithelial cells with very high yields. The invention further includes cell culture media formulations for the efficient maintenance, propagation, and maturation of cultured retinal pigmented epithelial cells.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 4, 2016
    Assignee: The Regents of the University of California
    Inventors: Dennis Clegg, David Buchholz, Roxanne Croze, Britney Pennington, Peter Coffey, Lyndsay Leach
  • Patent number: 9453203
    Abstract: The present invention relates to a method and to vectors for the immortalisation of cells independent of their type. It further relates to a cell or a cell line produced with the method or the vectors of the invention. The invention also relates to the use of this cell or cell line in in vitro applications and in the treatment of disease.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: September 27, 2016
    Assignee: Helmholtz-Zentrum Fur Infektionsforschung
    Inventors: Tobias May, Hansjörg Hauser, Franziska Klein, Jeannette Zauers, Roland Schucht
  • Patent number: 9447377
    Abstract: The present inventions describes a method that, starting from pluripotent cells, leads to the obtainment, in a reproducible and efficient manner, of endodermal cells precursor. These cells reveal useful also for application in the regenerative therapy.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: September 20, 2016
    Inventors: Stefania Filosa, Genesia Manganelli
  • Patent number: 9435811
    Abstract: This invention provides a method for administration of an effective amount of RANKL-binding molecules that act on prechondrocytes and/or mesenchymal stem cells, accelerate cartilage differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, and induce chondrocyte proliferation to induce chondrocyte proliferation and differentiation or increase cartilage matrix production and a pharmaceutical composition used for inducing chondrocyte proliferation and differentiation or increasing cartilage matrix production.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: September 6, 2016
    Assignee: ORIENTAL YEAST CO., LTD
    Inventors: Hisataka Yasuda, Yuriko Furuya
  • Patent number: 9410123
    Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: August 9, 2016
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Robert Lanza, Shi-Jiang Lu
  • Patent number: 9404087
    Abstract: A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: August 2, 2016
    Assignee: Kadimastem Ltd.
    Inventors: Michel Revel, Judith Chebath, Guy Slutsky, Alon Levy, Michal Izrael, Arik Hasson, Kfir Molakandov, Rosalia Kaufman
  • Patent number: 9394522
    Abstract: Provided are improved methods using Glycogen synthase kinase 3 (GSK3) inhibitors by which endodermal cells, notably endodermal cells derived from human pluripotent stem cells (hPS), such as but not limited to hiPS-cells and hES-cells may be differentiated into hepatocyte like cells. The specific modulation of wingless integration gene (WNT)-signalling pathway and use of GSK3 inhibitors achieve direct differentiation and maturation of hepatocytes derived from human pluripotent stem (hPS) cells. GSK-3 inhibitors, when added to the growth medium at certain developmental stages, leads to more mature and functional features for the hepatocyte like cells as well as more pure and homogenous populations of hepatocyte like cells. Provided are also hepatocyte like cells obtained by these methods as well as compositions comprising them.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: July 19, 2016
    Assignee: Takara Bio Europe AB
    Inventors: Gabriella Brolén, Josefina Edsbagge
  • Patent number: 9394523
    Abstract: A method of generating pluripotent stem cells is described. The method comprises: (a) expanding human pancreatic beta cells; and subsequently (b) generating induced pluripotent stem (iPS) cells from the human pancreatic beta cells. Methods of redifferentiating the iPS cells into particular cell types are also disclosed. Uses of the cell populations are also described.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: July 19, 2016
    Assignees: Ramot at Tel-Aviv University Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Shimon Efrat, Nissim Benvenisty
  • Patent number: 9388387
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides a method to increase the expression of markers associated with the pancreatic endocrine lineage.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: July 12, 2016
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania